Frequently asked questions

Seerlinq HeartCore is a non-invasive remote monitoring system that estimates left ventricular filling pressure (LVFP) from a short measurement patients take at home with a pulse oximeter. It helps care teams detect worsening heart failure before symptoms appear. HeartCore is CE-certified under the EU MDR as a Class IIb medical device.

HeartCore analyses the heart's response to a simple preload challenge: the patient moves from standing to lying down. This change in venous return is reflected in the photoplethysmography (PPG) signal at the fingertip.

A heart with normal filling pressure adapts efficiently to the change. Elevated LVFP impairs that adaptation and produces distinct PPG signal patterns, which HeartCore's proprietary signal analysis converts into an LVFP assessment.

Elevated LVFP is one of the earliest hemodynamic signs of worsening heart failure. In many patients it rises days to weeks, sometimes up to 4 weeks, before symptoms appear.

Weight, vital signs and symptoms often change late, when congestion is already well advanced. Telemonitoring built on these signals has shown only limited benefit in large randomised trials. Filling pressure rises earlier, often days to weeks before symptoms, giving clinicians time to act before decompensation.

Remote management guided by filling pressure has improved quality of life, reduced heart failure hospitalizations and improved survival. Until now, it required an implanted sensor: an invasive procedure, antithrombotic therapy, and risks such as infection, bleeding and device failure.

HeartCore provides hemodynamic information non-invasively with a pulse oximeter. There is no procedure, the hardware costs far less, and it can be used outside specialised heart failure centres.

• Non-invasive, home-based monitoring
• Validated against right-heart catheterization
• Validated across the full ejection fraction range, from HFrEF to HFpEF
• Works in patients with atrial fibrillation
• Low-cost, familiar hardware
• CE-certified medical device (MDR Class IIb)
• Modular architecture that integrates with existing remote patient monitoring platforms

No. HeartCore is based on cardiovascular physiology: it measures how the heart responds to the change in venous return when the patient moves from standing to lying down. The algorithm uses fixed, deterministic signal processing. It does not change after deployment, and the same measurement always gives the same result. Other Seerlinq products, such as atrial fibrillation detection, are developed separately and may use AI.

No. Echocardiography remains an essential diagnostic tool. HeartCore complements standard care with frequent, longitudinal monitoring between clinic visits.

For detecting elevated left ventricular filling pressure, HeartCore achieved an ROC AUC of 0.96 against right-heart catheterization and 0.88 against echocardiography. [link to publication – JACC HF September 2026 kde su aj gifures nejake]

HeartCore has been validated against invasive and non-invasive reference standards: right-heart catheterization and echocardiography. Prospective real-world studies have shown low hospitalization and mortality rates among monitored heart failure patients. [links to publications]

Yes. HeartCore has been validated across all major heart failure phenotypes: HFpEF, HFmrEF and HFrEF. This matters most for HFpEF patients, who are often underserved by existing monitoring options.

Yes. Filling pressures often rise weeks before clinical symptoms. HeartCore detects these hemodynamic changes early, so clinicians can adjust treatment before hospitalization becomes necessary.

HeartCore is approved for the non-invasive assessment and monitoring of left ventricular filling pressure, a key marker of worsening heart failure. Clinical studies of telemonitoring programs using HeartCore have observed fewer heart failure hospitalizations through earlier detection and intervention.

Patients take a simple 4-minute measurement at home: 2 minutes standing, then 2 minutes lying down. They use a Seerlinq pulse oximeter connected to the Seerlinq HF app on their smartphone via Bluetooth.

Most patients measure every other day.

No. The system is designed for independent home use and needs minimal training. The care team enrolls the patient and sets up the device during a clinic visit.

Yes. The solution was designed for older patients, including those with limited digital skills. The average age of patients monitored with HeartCore is 70.

Yes. The measurement is familiar, simple and takes only four minutes. Patients monitored with HeartCore in Slovakia complete almost 80% of their scheduled measurements, and 81% are still being monitored after one year.

Patients use the free Seerlinq HF app, available for iOS and Android.

The app currently supports 27 language options: English, Slovak, German, Polish, Italian, Swedish, Hebrew, Hungarian, Spanish, Portuguese, French, Danish, Norwegian, Lithuanian, Latvian, Russian, Ukrainian, Greek, Turkish, Traditional Chinese, Arabic, Azerbaijani, Czech, Hindi, Japanese, Romanian, and Simplified Chinese.

The core measurement uses a Seerlinq pulse oximeter. The platform also supports blood pressure monitors, personal scales and the AliveCor KardiaMobile (single-lead) and KardiaMobile 6L (6-lead) ECGs (additional pricing applies). A smartwatch-based application is in development.

Patients return the devices to their clinic, which can reuse them for the next patient. Devices not needed for a longer period can be sent back to Seerlinq's logistics centre.

The patient's healthcare team. Seerlinq provides the remote monitoring platform (Seerlinq CLV) that care teams use to review and act on patient data. In some countries, Seerlinq can also provide additional medical monitoring and patient-support services.

Clinicians receive actionable alerts and trend information in the platform. The platform comes with a standard set of alerts, which can be adjusted to each practice's preferences.

• Diuretic adjustments
• Medication optimization
• Investigation of triggers such as atrial fibrillation or infection
• Dietary counselling
• Additional clinical assessment when needed

• Centralized patient records: medical history, comorbidities, medications, clinical events and documentation
• Automatic capture of HeartCore measurements, vital signs, symptoms and patient-reported outcomes from the app
• Longitudinal trends of LVFP, symptoms, blood pressure, heart rate, ECG and other parameters
• Medical monitoring room with risk-based triage, so clinicians see first the patients who need attention
• Technical room for non-medical alerts, including measurement adherence
• Clinical event tracking entered by the site: hospitalizations, visits, medication changes, interventions, lab results and adverse events
• Multi-device monitoring
• Encrypted storage and transmission in a secure European telemedicine environment

In our experience, one full-time heart failure telemonitoring nurse can manage around 300 patients per month.

Yes. The platform is built on a modular architecture with a REST API documented in the OpenAPI standard. It can run as a standalone application or as an integration module within an existing remote patient monitoring platform. Integration partners get access through a dedicated Seerlinq service account.

Most pilots launch within a few weeks, including clinician onboarding, patient training and workflow setup. The full onboarding phase takes about one month.

• Patients recently hospitalized for heart failure
• NYHA class II–III patients
• Patients at high risk of decompensation
• Patients undergoing GDMT optimization
• HFpEF patients, who are often underserved by existing monitoring

Typical pilots involve 20–100 heart failure patients, enough to evaluate clinical and economic outcomes meaningfully.

During onboarding, Seerlinq ships the devices to your site, trains your staff, and prepares patient materials and consent forms tailored to your site. Your team then selects and enrolls patients, and creates, manages and monitors their patients independently.

Training typically takes one one-hour onboarding session. We explain how the monitoring platform works, how to onboard patients and how the patient app works, and walk through examples of patient reports and data. Your team also receives offline training materials on using the platform and onboarding patients, and the Seerlinq Physician Handbook, a guide to working with the monitoring data in clinical practice.

Every clinician gets a personal account on the Seerlinq CLV platform, secured with multi-factor authentication (MFA). The platform is available in English, German, Italian, Polish and Slovak.

• Clinical onboarding and staff training
• Technical support by email at support@seerlinq.com and by phone, on working days during standard business hours
• Patient support
• Workflow optimization

Seerlinq hosts and maintains the platform and develops new features. The platform and patient app improve continuously, and your team always has the latest version.

HeartCore is commercially available and fully reimbursed in Slovakia and Germany. In other EU countries, it is offered through pilots, local validations, distributor partnerships and market-entry programs. Outside the EU, HeartCore is becoming available in selected countries, depending on local regulatory requirements, and Seerlinq is pursuing FDA clearance for the United States. For current availability in your country, contact partner@seerlinq.com.

Yes. HeartCore is fully reimbursed in Slovakia and Germany. In other European markets, it is designed to support existing reimbursement pathways, for example where telemonitoring is reimbursed as a medical service provided by the care team.

HeartCore lets providers offer reimbursable remote monitoring services where telemonitoring is reimbursed, as well as additional and premium monitoring programs. Fewer unplanned visits and echocardiography exams free capacity for other procedures and patients. Where early readmissions are not covered, avoiding them also protects the provider’s budget.

HeartCore can generate value for healthcare systems through fewer heart failure hospitalizations and readmissions, fewer unplanned visits and echocardiography exams, and more quality-adjusted life years (QALYs) for patients. Care shifts from the hospital to the patient’s home, freeing hospital and specialist capacity for other procedures and patients. This comes from a proactive approach to care: elevated filling pressure flags patients at risk of decompensation, treatment can be adjusted before symptoms appear, and timely intervention can help avoid hospitalizations due to worsening heart failure.

Yes. HeartCore is CE-certified under the EU MDR as a Class IIb medical device.

Not yet. Seerlinq has completed the FDA Q-Submission process and is pursuing a 510(k) pathway.

Patient data is encrypted in transmission and storage and hosted in a secure European telemedicine environment built for healthcare. Processing complies with healthcare data protection requirements, including GDPR.

In Seerlinq's formal assessment, the currently deployed production version of HeartCore is not an AI system under Article 3(1) of the EU AI Act. It is a fully deterministic signal-processing system with no machine-learning, adaptive or probabilistic components.

Yes. A PCT patent application has been filed and is in the national phase in Europe and the United States.

Yes. Seerlinq recently added atrial fibrillation detection. The research pipeline also includes arrhythmias, heart attack detection, and anemia and bleeding detection.

Yes. Seerlinq is collaborating with a leading smartwatch manufacturers on a smartwatch-based heart failure screening and monitoring application.

To democratize precision medicine in heart failure, so that every patient can benefit from personalized care, not only those treated in specialized centers. In the long term, we want to turn widely available PPG sensors, including pulse oximeters and smartwatches, into a global platform for early detection, monitoring and prevention of cardiovascular disease.